Law Mansun, Maruyama Toshiaki, Lewis Jamie, Giang Erick, Tarr Alexander W, Stamataki Zania, Gastaminza Pablo, Chisari Francis V, Jones Ian M, Fox Robert I, Ball Jonathan K, McKeating Jane A, Kneteman Norman M, Burton Dennis R
Department of Immunology, The Scripps Research Institute, 10550 North Torrey Pines Road, La Jolla, California 92037, USA.
Nat Med. 2008 Jan;14(1):25-7. doi: 10.1038/nm1698. Epub 2007 Dec 6.
A major problem in hepatitis C virus (HCV) immunotherapy or vaccine design is the extreme variability of the virus. We identified human monoclonal antibodies (mAbs) that neutralize genetically diverse HCV isolates and protect against heterologous HCV quasispecies challenge in a human liver-chimeric mouse model. The results provide evidence that broadly neutralizing antibodies to HCV protect against heterologous viral infection and suggest that a prophylactic vaccine against HCV may be achievable.
丙型肝炎病毒（HCV）免疫疗法或疫苗设计中的一个主要问题是该病毒的高度变异性。我们鉴定出了能中和基因多样的HCV分离株并在人肝脏嵌合小鼠模型中抵御异源HCV准种攻击的人单克隆抗体（mAb）。这些结果证明针对HCV的广泛中和抗体可抵御异源病毒感染，并表明针对HCV的预防性疫苗或许是可以实现的。
